Paul Hastings Advised Piper Sandler & Co., Oppenheimer & Co. in Connection With Skye Bioscence PIPE
March 13, 2024
March 13, 2024
LOS ANGELES, California, March 13 -- Paul Hastings, a law firm, issued the following news on March 12, 2024:
Paul Hastings LLP advised Piper Sandler and Co. as lead placement agent, and Oppenheimer & Co. as placement agent in connection with Skye Bioscence, Inc.'s private placement (PIPE).
The PIPE consists of the sale of 4,000,000 shares of common stock at $10.00 per share to certain investors. Skye, Inc., (OTCQB: SKYE) is a clinical stage biotechnology compa . . .
Paul Hastings LLP advised Piper Sandler and Co. as lead placement agent, and Oppenheimer & Co. as placement agent in connection with Skye Bioscence, Inc.'s private placement (PIPE).
The PIPE consists of the sale of 4,000,000 shares of common stock at $10.00 per share to certain investors. Skye, Inc., (OTCQB: SKYE) is a clinical stage biotechnology compa . . .